The present disclosure relates generally to the field of pharmaceuticals. Specifically, thepresent disclosure is directed to a compound, diminazene aceturate, for the treatment,amelioration, attenuation or prevention of diazepam dependence induced withdrawalsyndrome. Diminazene aceturate is an ASIC1a modulator and the withdrawal symptoms areprecipitated using flumazenil.
Inventors
Gurjeet Thakur, Amarjot Kaur Grewal
